Potentiation of in vitro and in vivo antitumor efficacy of doxorubicin by cyclin-dependent kinase inhibitor P276-00 in human non-small cell lung cancer cells

BMC Cancer

Maggie J Rathos¹  Harshal Khanwalkar¹  Kavita Joshi¹  Sonal M Manohar¹  Kalpana S Joshi² 

[1] Oncology Franchise, Piramal Healthcare Limited, 1-Nirlon Complex, Goregaon, Mumbai, 400 063, India

[2] Target Identification Group, Piramal Healthcare Limited, 1-Nirlon Complex, Goregaon, Mumbai, 400 063, India

关键词: Chemotherapy;    Cyclin-dependent kinase inhibitor;    Doxorubicin;    P276-00;    Non-small cell lung cancer;   

Others  :  1079961
DOI  :  10.1186/1471-2407-13-29

 received in 2012-09-13, accepted in 2013-01-16,  发布年份 2013

【 摘 要 】

Background

In the present study, we show that the combination of doxorubicin with the cyclin-dependent kinase inhibitor P276-00 was synergistic at suboptimal doses in the non-small cell lung carcinoma (NSCLC) cell lines and induces extensive apoptosis than either drug alone in H-460 human NSCLC cells.

Methods

Synergistic effects of P276-00 and doxorubicin on growth inhibition was studied using the Propidium Iodide (PI) assay. The doses showing the best synergistic effect was determined and these doses were used for further mechanistic studies such as western blotting, cell cycle analysis and RT-PCR. The in vivo efficacy of the combination was evaluated using the H-460 xenograft model.

Results

The combination of 100 nM doxorubicin followed by 1200 nM P276-00 showed synergistic effect in the p53-positive and p53-mutated cell lines H-460 and H23 respectively as compared to the p53-null cell line H1299. Abrogation of doxorubicin-induced G2/M arrest and induction of apoptosis was observed in the combination treatment. This was associated with induction of tumor suppressor protein p53 and reduction of anti-apoptotic protein Bcl-2. Furthermore, doxorubicin alone greatly induced COX-2, a NF-κB target and Cdk-1, a target of P276-00, which was downregulated by P276-00 in the combination. Doxorubicin when combined with P276-00 in a sequence-specific manner significantly inhibited tumor growth, compared with either doxorubicin or P276-00 alone in H-460 xenograft model.

Conclusion

These findings suggest that this combination may increase the therapeutic index over doxorubicin alone and reduce systemic toxicity of doxorubicin most likely via an inhibition of doxorubicin-induced chemoresistance involving NF-κB signaling and inhibition of Cdk-1 which is involved in cell cycle progression.

【 授权许可】

   
2013 Rathos et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Ko J-C, Wang L-H, Jhan J-Y, Ciou S-C, Hong J-H: The role of celecoxib in Rad51 expression and cell survival affected by gefitinib in human non-small cell lung cancer cells. Lung Cancer 2009, 65:290-298.
• [2]Jin H-O, Seo S-K, Woo S-H, Lee H-C, Kim E-S, Yoo D-H, Lee S-J, An S, Choe T-B, Kim J-I, Hong S-I, Rhee C-H, Park I-C: A combination of sulindac and arsenic trioxide synergistically induces apoptosis in human lung cancer H1299 cells via c-Jun NH2-terminal kinase-dependent Bcl-xL phosphorylation. Lung Cancer 2008, 61:317-327.
• [3]Skarda J, Hajdúch M, Kolek V: Drug resistance in lung cancer. Cancer Therapy 2008, 6:377-388.
• [4]Han YH, Park WH: Growth inhibition in antimycin A treated-lung cancer Calu-6 cells via inducing a G1 phase arrest and apoptosis. Lung Cancer 2009, 65:150-160.
• [5]Mi J, Zhang X, Rabban ZN, Liu Y, Reddy SK, Su Z, Salahuddin FK, Viles K, Giangrande PH, Dewhirst MW, Sullenger BA, Kontos CD, Clary BM: RNA aptamer-targeted inhibition of NF-κB suppresses non-small cell lung cancer resistance to doxorubicin. Mol Ther 2008, 16(1):66-73.
• [6]Yee KS, Vousden KH: Complicating the complexity of p53. Carcinogenesis 2005, 26:1317-1322.
• [7]Kodym E, Kodym R, Reis AE, Habib AA, Story MD: The small-molecule CDK inhibitor, SNS-032, enhances cellular radiosensitivity in quiescent and hypoxic non-small cell lung cancer cells. Lung Cancer 2009, 66:37-47.
• [8]Tanaka H, Fujii Y, Hirabayashi H, Miyoshi S, Sakaguchi M, Yoon H-E, Matsuda H: Disruption of the Rb pathway and cell-proliferative activity in non-small-cell lung cancers. Int J Cancer (Pred. Oncol.) 1998, 79:111-115.
• [9]Ratschiller D, Heighway J, Gugger M, Kappeler A, Pirnia F, Schmid RA, Borner MM, Betticher DC: Cyclin D1 overexpression in bronchial epithelia of patients with lung cancer is associated with smoking and predicts survival. J Clin Oncol 2003, 21(11):2085-2093.
• [10]Joshi KS, Rathos MJ, Joshi RD, Sivakumar M, Mascarenhas M, Kamble S, Lal B, Sharma S: In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00. Mol Cancer Ther 2007, 6(3):918-925.
• [11]Joshi KS, Rathos MJ, Mahajan P, Wagh V, Shenoy S, Bhatia D, Chile S, Sivakumar M, Maier A, Fiebig H-H, Sharma S: P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol Cancer Ther 2007, 6(3):926-934.
• [12]Manohar SM, Rathos MJ, Sonawane V, Rao SV, Joshi KS: Cyclin-dependent kinase inhibitor P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription. Leukemia Res 2011, 35(6):821-830.
• [13]Vatsyayan R, Chaudhary P, Rao Lelsani PC, Singhal P, Awasthi YC, Awasthi S, Singhal SS: Role of RLIP76 in doxo resistance in lung cancer. Int J Oncol 2009, 34(6):1505-1511.
• [14]Chou T-C: Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006, 58:621-681.
• [15]Takezawa K, Okamoto I, Yonesaka K, Hatashita E, Yamada Y, Fukuoka M, Nakagawa K: Sorafenib inhibits non-small cell lung cancer growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells. Cancer Res 2009, 69(16):6515-6521.
• [16]Singh RP, Mallikarjuna GU, Sharma G, Dhanalakshmi S, Tyagi AK, Chan DC, Agarwal C, Agarwal R: Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor κB-mediated inducible chemoresistance. Clin Cancer Res 2004, 10:8641-8647.
• [17]Lambert LA, Qiao N, Hunt KK, Lambert DH, Mills GB, Meijer L, Keyomarsi K: Autophagy: a novel mechanism of synergistic cytotoxicity between doxo and roscovitine in a sarcoma model. Cancer Res 2008, 68(19):7966-7974.
• [18]Lowe SW, Lin AW: Apoptosis in cancer. Carcinogenesis 2000, 21:485-495.
• [19]O’Loughlin C, Heenan M, Coyle S, Clynes M: Altered cell cycle response of drug-resistant lung carcinoma cells to doxo. Eur J Cancer 2000, 36:1149-1160.
• [20]Varmeh S, Manfredi JJ: Overexpression of the dual specificity phosphatase, Cdc25c, confers sensitivity on tumor cells to doxo-induced cell death. Mol Cancer Ther 2008, 7:3789-3799.
• [21]Rom WN, Tchou-Wong K-M: Functional genomics in lung cancer and biomarker detection. Am J Respir Cell Mol Biol 2003, 29:153-156.
• [22]Coe BP, Lockwood WW, Girard L, Chari R, MacAulay C, Lam S, Gazdar AF, Minna JD, Lam WL: Differential disruptiona of cell cycle pathways in small cell and non-small cell lung cancer. Br J Cancer 2006, 94:1927-1935.
• [23]O’Kane SL, Eagle GL, Greenman J, Lind MJ, Cawkwell L: COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines. Lung Cancer 2010, 67(2):160-165.
• [24]Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L: Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004, 56:185-229.